NHE-1 and NHE-6 Activities
Ischemic and Reperfusion Injury
H.E. Cingolani, I.L. Ennis, S.M. Mosca

The study published in this issue of Circulation Research showing that a null mutation of NHE-1 improves the tolerance of the heart to ischemia and reperfusion (I/R) is an important contribution for the following reasons: (1) In the animals with null mutation, contracture during the ischemic period was less and ATP levels were preserved compared with wild-type animals. This observation, on the one hand, provides evidence that protection by downregulation of NHE-1 during the ischemic period itself is indeed possible and, on the other hand, it argues against the suggestion that the exchanger is inactive during this same period. In contrast with chronic blockade of the NHE-1, protection by blocking its activity for a relative short term. This point is related to a recent publication showing that long-term treatment with the NHE-1 blocker cariporide is followed by an upregulation of the functional units of the exchanger in a similar way to the well-known tolerance phenomenon following β-adrenergic receptor blockade. The absence of such upregulation negates possible hypersensitivity to ischemia upon withdrawal of the medication. The risk is evident in hearts with upregulation of NHE-1, which gain Na⁺/H⁻ more rapidly during ischemia, and show impaired recovery after reperfusion.

(3) No additional protection was obtained by adding the NHE-1 blocker eniporide to the NHE-1 null mice, suggesting that there is not another NHE isoform that can be blocked with this compound to add additional protection; the findings additionally hint that the attenuation of the injury obtained by the absence of the sarcolemmal NHE-1 is maximal and, therefore, no further beneficial effect will be detected by blocking the mitochondrial NHE (MNHE).

The classical explanation of the mechanism by which the NHE-1 blockade protects against I/R is as follows. During ischemia, a cytosolic acidosis of approximately 1 pH unit occurs in about 10 minutes. This cytosolic acidosis stimulates the NHE-1, increasing its activity and augmenting cytosolic Na⁺ and Ca²⁺ levels. Although other mechanisms could contribute to the increase in intracellular Na⁺ (Na⁺/H⁻) during ischemia, it has been shown that blockade of the NHE-1 before ischemia abolishes the increase in Na⁺ during this period and diminishes the increase in cytosolic Na⁺ and Ca²⁺ during reperfusion. The increase in Ca²⁺ secondary to the increase in Na⁺ seems to be caused by the Na⁺/Ca²⁺ exchanger (NCX) working in reverse mode, and cytosolic Ca²⁺ overload is a necrotic and apoptotic signal. Although with some contradictory results, it has been possible to obtain protection from I/R by blocking the NHE-1 or the NCX only after the onset of reperfusion, suggesting that there is protection against the reperfusion injury induced by these mechanisms in addition to protection from the ischemic injury.

Although other mechanisms can be operative, the activation of NHE-1 at the onset of reperfusion has been linked to the increase in reactive oxygen species (ROS). This exchanger reaches its maximal activity early after reperfusion. It has been proposed that the increase in ROS leads to activation of the mitogen-activated protein kinase pathway, phosphorylating ERK1/2 and the cytosolic tail of the NHE-1, increasing the exchanger activity. On the other hand, it has been also reported that ERK1/2 mediates activation of the Na⁺/HCO₃⁻ cotransport and that blockade of this mechanism protects against I/R injury.

The available evidence, therefore, establishes that the cytosolic Ca²⁺ overload induced by the NCX working in reverse mode can be prevented by blocking the NHE-1, decreasing Na⁺. A recent publication makes things more difficult to interpret. In this study, the authors showed that cariporide preserves mitochondrial proton gradient and delays ATP depletion in mouse-derived myocytes (HL-1) after simulated ischemia and suggested that these mitochondrial changes are not secondary to changes in the cytosol. They concluded that, during ischemia, cariporide acts at the mitochondrial level, delaying mitochondrial matrix acidification and preserving ATP levels. They also suggested that the prevention of mitochondrial Ca²⁺ overload was not cariporide’s mechanism of protection.

Mitochondrial NHE (MNHE) is apparently encoded by NHE-6, with a molecular structure similar to that of NHE-1. However, there are still some concerns about the identification of the NHE-6 with the MNHE. The MNHE can be blocked by several NHE blockers including cariporide; therefore, this drug blocks both the NHE-1 (sarcolemmal) and the NHE-6 (mitochondrial) gene products.

In a more recent study, the effect of cariporide on cell death induced by oxidative stress was examined in cultured neonatal cardiomyocytes. The inhibitor suppressed cytosolic Na⁺ and Ca²⁺ accumulation and the loss of mitochondrial...
membrane potential induced by H$_2$O$_2$, while also decreasing the mitochondrial Ca$^{2+}$ overload induced by H$_2$O$_2$. Despite the decrease in cytosolic and mitochondrial Ca$^{2+}$ overload, their results suggested a contribution of two Ca$^{2+}$-independent pathways: calcium-independent cell death and calcium-independent cytochrome c release induced by the blocker. These results suggest that NHE-1 blockade preserves mitochondrial integrity after oxidant stress. These actions were not blunted by mitochondrial K$_{ATP}$ channel blockers, revealing different mechanisms of protection from those operative in ischemic preconditioning. Although some studies have suggested that NHE-1 inhibition and ischemic preoperative in ischemic preconditioning. Although some studies have suggested that NHE-1 inhibition and ischemic preconditioning are linked phenomena, this$^{25}$ and other studies$^{26-29}$ provide evidence that this is not the case. Moreover, experiments in isolated rat hearts comparing ischemic preconditioning with NHE inhibition showed that, although after reperfusion protection was similar, only the NHE inhibition was able to decrease the ischemic contracture.$^{26}$

How can we reconcile the evidence that null mutation of the NHE-1 induces protection from ischemia/reperfusion and that cariporide also protects against ischemia/reperfusion but acting on another isof orm? The simplest explanation is that, although the downregulation of the NHE-1 by its ablation by genetic techniques protects the heart from ischemia/reperfusion, additional protection can be obtained by the blockade of MNHE (NHE-6) with the compound. However, the investigators did not accomplish additional protection from I/R when a blocker of the NHE-1, eniporide, was added to the animals with the null mutation of the NHE-1. Among the possibilities to understand this discrepancy, we should consider the following: first, that NHE-1 is not only the sarcocellosomal isoform of the NHE but also the mitochondrial one; second, that the genetic manipulation of these animals produced an unintentional downregulation or modification of the MNHE, making it “inactive” for the ischemic/reperfusion injury; third, that the attenuation of the injury obtained with the blockade of the NHE-1 is maximal and so no further beneficial effect will be detected blocking the MNHE.

New avenues of research begin with the novel contributions of these studies about the reperfusion injury process. Should we consider the existence of two protections, one during ischemia and the other one during reperfusion, each mediated by a different NHE isof orm? Is the acidification of the cytosol a change that attenuates the reperfusion injury, in contrast to the same change in the mitochondrial matrix? What is the role of NCX in cytosol and mitochondrial Ca$^{2+}$ overload? May Ca$^{2+}$ overload in one compartment protect the other? Should we consider the downregulation of the heart NHE by genetic techniques a gene therapy possibility? All are questions that should be answered in the near future.

In contrast with the promising results coming from studies in several animal species and NHE inhibitors, clinical trials have not shown unequivocal evidence of this protection. The GUARDIAN,$^{30}$ ESCAMI,$^{31}$ and EXPEDITION$^{32}$ trials are examples of such disappointment. The latter was started in 2001 and stopped 6 months later for reasons unreleased to the public. The strikingly beneficial effects of NHE inhibition in well-controlled experimental systems give reason to hope that future drug trials may prove the clinical utility of this therapeutic principle.

References


**KEY WORDS:** myocardial infarction □ NHE-1 □ NHE-6 □ apoptosis □ necrosis
NHE-1 and NHE-6 Activities: Ischemic and Reperfusion Injury
H.E. Cingolani, I.L. Ennis and S.M. Mosca

Circ Res. 2003;93:694-696
doi: 10.1161/01.RES.0000097926.29243.96
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2003 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/93/8/694

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org//subscriptions/